Skip to main content
Article thumbnail
Location of Repository

Cryptosporidium parvum, a potential cause of colic adenocarcinoma

By Gabriela Certad, Tramy Ngouanesavanh, Karine Guyot, Nausicaa Gantois, Thierry Chassat, Anthony Mouray, Laurence Fleurisse, Anthony Pinon, Jean-Charles Cailliez, Eduardo Dei-Cas and Colette Creusy
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2217515
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). 3rd: Chemically and genetically immunocompromised mice are not more susceptible than immunocompetent mice to infection with Cryptosporidium muris. Vet Parasitol
  2. (2003). A: Population structures and the role of genetic exchange in the zoonotic pathogen Cryptosporidium parvum.
  3. (2005). Anatomy and physiology of the stomach. Surg Clin North Am
  4. (2005). Association of parasitic infections and cancers.
  5. (2001). Aural-pharyngeal polyps associated with Cryptosporidium infection in three iguanas (Iguana iguana). Vet Pathol
  6. (2002). Chappell CL: Cryptosporidium virulence determinants--are we there yet?
  7. (1991). Chronic Cryptosporidium parvum infections in congenitally immunodeficient SCID and nude mice.
  8. (1984). DB: Persistent Cryptosporidium infection in congenitally athymic (nude) mice. Infect Immun
  9. (2006). Dei-Cas E, Banuls AL: Cryptosporidium Population Genetics: Evidence of Clonality in Isolates from France and Haiti.
  10. (2006). Emergence of distinct genotypes of Cryptosporidium parvum in structured host populations. Appl Environ Microbiol
  11. (1994). Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrumimmunoglobulin. Clin Diagn Lab Immunol
  12. (1992). Immune responses to Cryptosporidium muris and Cryptosporidium parvum in adult immunocompetent or immunocompromised (nude and SCID) mice. Infect Immun
  13. (2001). Interferon gamma induces enterocyte resistance against infection by the intracellular pathogen Cryptosporidium parvum. Gastroenterology
  14. (1995). Intestinal and extraintestinal cryptosporidiosis in AIDS patients.
  15. (2001). LaRusso NF: Cryptosporidium parvum activates nuclear factor kappaB in biliary epithelia preventing epithelial cell apoptosis. Gastroenterology
  16. (2006). Lett Appl Microbiol
  17. (2003). MD: Colorectal malignancies in HIV-positive patients. Am Surg
  18. (2003). Microsatellite analysis of Cryptosporidium hominis and C. parvum in Portugal: a preliminary study.
  19. (1999). Mouse models for colorectal cancer. Oncogene
  20. (1995). Murine infection model for maintenance and amplification of Cryptosporidium parvum oocysts.
  21. (2004). Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies.
  22. (1981). Pohlenz JF: Staining of cryptosporidia by a modified Ziehl-Neelsen technique. Acta Vet Scand
  23. (2006). Pozio E: Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert Rev Anti Infect Ther
  24. (2004). Pozio E: Cryptosporidium parvum at different developmental stages modulates host cell apoptosis in vitro. Infect Immun
  25. (2002). Recent advances in cryptosporidiosis: the immune response. Microbes Infect
  26. (2004). RP: Cryptosporidiosis of the biliary tract mimicking pancreatic cancer in an AIDS patient. Rev Soc Bras Med Trop
  27. (2007). Schaefer FW 3rd: Characterization of a Cryptosporidium muris infection and reinfection in CF-1 mice. Vet Parasitol
  28. (1994). Schinazi RF: Infection dynamics and clinical features of cryptosporidiosis in SCID mice. Infect Immun
  29. (1996). SCID mice and the study of parasitic disease. Clin Microbiol Rev
  30. (1993). Shultz LD: The Severe Combined Immunodeficiency (scid) Mutation.
  31. (2004). SJ: Cryptosporidium taxonomy: recent advances and implications for public health. Clin Microbiol Rev
  32. (1989). Takada S: Infectivity of Cryptosporidium muris (strain RN 66) in various laboratory animals. Parasitol Res
  33. (2006). Taketo MM: Mouse models of gastrointestinal tumors. Cancer Sci
  34. (2007). Telatynska-Smieszek B: Cryptosporidiosis in patients with colorectal cancer.
  35. (2003). Thamsborg SM: Pathogenicity of Cryptosporidium parvum--evaluation of an animal infection model. Vet Parasitol
  36. (2002). The global health burden of infection-associated cancers in the year
  37. (2005). The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol
  38. (2003). The new Vienna classification of epithelial neoplasia of the gastrointestinal tract: advantages and disadvantages. Virchows Arch
  39. (1999). The pathogenesis of experimental infections of Cryptosporidium muris (strain RN 66) in outbred nude mice. Vet Parasitol
  40. (2007). Tomic-Canic M: Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation.
  41. (2002). Tzipori S: Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-g knockout mice.
  42. (2005). Tzipori S: Kinetics of Cryptosporidium parvum-specific cytokine responses in healing and nonhealing murine models of C. parvum infection. Parasitol Res
  43. (2007). Wang TC: Inflammation, atrophy, and gastric cancer.
  44. (2001). White AC Jr.: Expression of IL-15 and IL-4 in IFN-gammaindependent control of experimental human Cryptosporidium parvum infection. Cytokine

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.